NEC-CM104-100μg / 询价
NEC-CM104-500μg / 询价
NEC-CM104-500μgx2 / 询价
Cynomolgus Nectin-4 Protein
Recombinant Cynomolgus Nectin-4 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gly32-Val351.[Accession | XP_005541277.1]
The protein has a predicted MW of 35.9 kDa. Due to glycosylation, the protein migrates to 38-48 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus Nectin-4 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.
The purity of Cynomolgus Nectin-4 is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus Nectin-4, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-Nectin-4 Antibody, hFc Tag with the EC50 of 5.9ng/ml determined by ELISA.
Nectin-4 seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.(Microbial infection) Acts as a receptor for measles virus.
EDSS1; LNIR; Nectin4; PRR4; NECTIN4; PVRL4
(1)Challita-Eid P M , Satpayev D , Yang P , et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models[J]. Cancer Research, 2016:0008-5472.CAN-15-1313.
